Product Detail

loading

Share to:
facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

Cas No. 1374635-90-1, Spiro[cyclohexane pentane-1,8′(9′H )-pyrazino[1′,2′:1,5]pyrrolo[2,3-d ]pyrimidin]-6′(7′H )one, 2′-chloro- (ACI)

  • 1374635-90-1

  • C14H15ClN4O

  • 290.75

  • 1.60±0.1

  • 98% min

  • ES-SCLC

  • Trilaciclib; Lerociclib

  • 7/23/2039 (Trilaciclib)

  • CDK4/6

  • N

  • 2022

  • ISO 9001;ISO 14001;ISO 45001; GMP

Availability:
Inquire

Description

Trilaciclib revolutionizes the landscape of oncology therapeutics by protecting and preserving patients' bone marrow during chemotherapy. Trilaciclib's unique mechanism reduces the risk of chemotherapy-induced myelosuppression, enabling patients to undergo more effective and intensive treatment regimens. By ensuring a safer and more productive treatment journey, Trilaciclib optimizes patient outcomes and strengthens your company's commitment to advancing cancer care. Embrace this game-changer and pave the way for a new era in cancer therapeutics.

ROS

Synthesis of Trilaciclib; Root of Synthesis


Reference


- CN114014864A

- US20140274896A1

- WO2018005865

Previous: 
Next: 
Cas No. 1374635-90-1